PE20021161A1 - DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1) - Google Patents

DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1)

Info

Publication number
PE20021161A1
PE20021161A1 PE2002000241A PE2002000241A PE20021161A1 PE 20021161 A1 PE20021161 A1 PE 20021161A1 PE 2002000241 A PE2002000241 A PE 2002000241A PE 2002000241 A PE2002000241 A PE 2002000241A PE 20021161 A1 PE20021161 A1 PE 20021161A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
phenyl
alcoxyl
hvr1
Prior art date
Application number
PE2002000241A
Other languages
English (en)
Inventor
Andrew James Culshaw
Peter Gull
Hong-Yong Kim
Kaspar Zimmermann
Mahavir Prashad
Yugang Liu
Max Peter Seiler
Allan Hallett
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0107505A external-priority patent/GB0107505D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20021161A1 publication Critical patent/PE20021161A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIDINA DE FORMULA I DONDE R1 Y R2 SON JUNTOS -NHC(SR6)=N-CO-; -R7NC(R8)=NCO-, -N=C(SR9)NR10CO-, -NR11XNR12CO, NHXNH, -NHXN=CR13-, -NHXNHCH2-, -NZNH-, -N=ZNHCH2-, -N=ZNHCON=ZN=CR14-; X ES CO, CS, CO-CO, Z ES N, CR15; R6 ES ALQUILO C1-C4; R7 Y R8 SON H, ALQUILO C1-C4, CICLOALQUILO C3-C8 O FORMAN JUNTOS UN HETEROCICLO DE 5-6 MIEMBROS; R9 Y R10 JUNTOS SON ALQUILENO C1-C4; R11 ES H, ALQUILO C1-C4, FENILO; R12 ES H, NH2, ALQUILO C1-C4, FENILO; R13 ES H, HALOGENO, NH2, ALCOXILO C1-C4; R14 ES H, OH, HALOGENO, NH2, ALQUILO C1-C4, ALCOXILO C1-C4; R15 ES H, HALOGENO, ALQUILO C1-C4, ALCOXILO C1-C4, SCH2COOC(CH3)3; R3 ES H, OH, CN, ALQUILO C1-C6, FENILO, COO-ALQUILO C1-C4; R4 ES H, HALOGENO, NH2, CN, ALQUILO C1-C6, FENILO, ALCOXILO C1-C6, BENCILO, BENZOILO, COO-ALQUILO C1-C6, HETEROCICLO; R5 ES H, OH, NH2, HALOGENO, ALQUILO C1-C6, CICLOALQUILO C3-C6, FENILO, PIRIDINILO, NH-ALQUILO C1-C4, N-CHN-ALQUILO C1-C4, EXCEPTO LOS COMPUESTOS PIRIDO[3,2-d]-PIRIMIDIN-2,4(1H,3H)-DIONA; 6-CLORO-2-METIL-4-OXO-PIRIDO[3,2-d]PIRIMIDINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y UN PROCESO PARA PREPARAR 7-TERBUTIL-6-(4-CLOROFENIL)-2-TIOXO-2,3-DIHIDRO-1.H-PIRIDO[2,3-d]-PIRIMIDIN-4-ONA. LOS COMPUESTOS SON BLOQUEADORES FUNCIONALES DEL RECEPTOR VANILOIDE HUMANO 1 (hVR1) Y PUEDEN SER UTILES COMO AGENTES ANTIHIPERALGESICOS Y PARA EL TRATAMIENTO DE OSTEOARTRITIS DOLOR POR CANCER, LESION MUSCULAR, FIBROMIALGIA
PE2002000241A 2001-03-26 2002-03-26 DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1) PE20021161A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0107505A GB0107505D0 (en) 2001-03-26 2001-03-26 Organic compounds
US33828101P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
PE20021161A1 true PE20021161A1 (es) 2003-02-21

Family

ID=26245894

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000241A PE20021161A1 (es) 2001-03-26 2002-03-26 DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1)

Country Status (17)

Country Link
US (1) US7915264B2 (es)
EP (1) EP1377576A2 (es)
JP (1) JP4205430B2 (es)
KR (1) KR20030083755A (es)
CN (1) CN1500089A (es)
BR (1) BR0208338A (es)
CA (1) CA2441599A1 (es)
CZ (1) CZ20032561A3 (es)
HU (1) HUP0303623A2 (es)
IL (1) IL157815A0 (es)
MX (1) MXPA03008754A (es)
NO (1) NO326546B1 (es)
PE (1) PE20021161A1 (es)
PL (1) PL363907A1 (es)
RU (1) RU2003130221A (es)
SK (1) SK11952003A3 (es)
WO (1) WO2002076946A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004506714A (ja) 2000-08-21 2004-03-04 パシフィック コーポレーション 新規チオ尿素化合物及びこれを含有する薬学的組成物
ATE393141T1 (de) 2000-08-21 2008-05-15 Pacific Corp Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
KR20040085151A (ko) 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
JP4583760B2 (ja) 2002-02-01 2010-11-17 ユーロ−セルティーク エス.エイ. 疼痛の治療に有用な治療薬
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
ATE450533T1 (de) * 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20070135454A1 (en) 2003-11-14 2007-06-14 Tracy Bayliss Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
DE102004039373A1 (de) 2004-08-12 2006-02-23 Grünenthal GmbH Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
GB0506147D0 (en) * 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
US20090298856A1 (en) * 2005-05-11 2009-12-03 Rebecca Elizabeth Brown 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
AU2006303437B2 (en) * 2005-10-19 2012-06-28 Grunenthal Gmbh Novel vanilloid receptor ligands and their use for producing medicaments
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
KR100761222B1 (ko) * 2006-03-08 2007-10-04 성균관대학교산학협력단 약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
ES2399928T3 (es) 2006-08-23 2013-04-04 Neurogen Corporation Análogos de 2-fenoxipirimidinona
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
WO2008129000A1 (en) * 2007-04-20 2008-10-30 Novartis Ag Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders
CN101754774B (zh) 2007-07-18 2013-08-21 诺瓦提斯公司 Vr-1拮抗剂和cox-2抑制剂的协同组合
US8349846B2 (en) * 2008-01-11 2013-01-08 Glenmark Pharmaceuticals, S.A. Fused pyrimidine derivatives as TRPV3 modulators
WO2009121036A2 (en) * 2008-03-27 2009-10-01 Neurogen Corporation Substituted aryl pyrimidinone derivatives
ES2539290T3 (es) 2008-04-18 2015-06-29 Daewoong Pharmaceutical Co., Ltd. Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CN107108429B (zh) * 2015-12-23 2022-08-19 联邦科学与工业研究组织 化合物
CN108863949B (zh) * 2018-07-09 2021-01-15 湖南博隽生物医药有限公司 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂及合成方法
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2749344A (en) * 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5620978A (en) 1994-01-03 1997-04-15 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

Also Published As

Publication number Publication date
JP4205430B2 (ja) 2009-01-07
SK11952003A3 (sk) 2004-03-02
HUP0303623A2 (hu) 2004-03-01
CA2441599A1 (en) 2002-10-03
BR0208338A (pt) 2004-03-09
NO20034122D0 (no) 2003-09-16
CZ20032561A3 (cs) 2003-12-17
WO2002076946A3 (en) 2002-12-27
US7915264B2 (en) 2011-03-29
JP2004528312A (ja) 2004-09-16
RU2003130221A (ru) 2005-04-10
KR20030083755A (ko) 2003-10-30
CN1500089A (zh) 2004-05-26
US20040138454A1 (en) 2004-07-15
NO20034122L (no) 2003-09-16
MXPA03008754A (es) 2004-02-18
PL363907A1 (en) 2004-11-29
NO326546B1 (no) 2009-01-05
IL157815A0 (en) 2004-03-28
WO2002076946A2 (en) 2002-10-03
EP1377576A2 (en) 2004-01-07

Similar Documents

Publication Publication Date Title
PE20021161A1 (es) DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1)
RU2376287C2 (ru) Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac
CY1109263T1 (el) Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine
PE20020976A1 (es) Pirido-pirimidinas 6-sustituidas como inhibidores de quinasas
MXPA04003474A (es) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a.
JP2004527560A5 (es)
PE20020062A1 (es) 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a
AP2002002586A0 (en) Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
CY1107807T1 (el) Παρaγωγα πυριμιδiνης
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
PL207340B1 (pl) Związki imidazochinolinowe, środek farmaceutyczny i ich zastosowanie
CA2416274A1 (en) N-phenyl-2-pyrimidine-amine derivatives
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
RU2004106783A (ru) Производные 4-амино-6-фенилпирроло[2, 3] пиримидина
JP2004525868A (ja) 置換イミダゾピリジン類
JP2005508966A5 (es)
YU55603A (sh) Derivati purina kao antagonisti purinergiskog receptora
RU2009113612A (ru) Ацетамидные производные хиназолинона и изохинолинона
RU2350616C2 (ru) Производные пиразоло- и имидазопиримидина
RU2012144751A (ru) Гетероциклические соединения, эффективные для ингибирования киназы
PE20010401A1 (es) DERIVADOS DE 8-FENIL-6,9-DIHIDRO-[1,2,4] TRIAZOL [3,4-i] PURIN-5-ONA COMO INHIBIDORES DE FOSFODIESTERASA ESPECIFICA DE GMP CICLICO
HUP0400963A2 (hu) Antidiarrheás és perifériális analgetikus hatású helyettesített ciklohexán-1,4-diamin-származékok felhasználása gyógyszerkészítmények előállítására
WO2012167600A1 (zh) 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
RU2007146512A (ru) N, n-замещенные 3-аминопирролидиновые соединения, полезные в качестве ингибиторов повторного поглощения моноаминов

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed